Back to search

Article

Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational study

2024-04-05

Abstract excerpt

<title>Abstract</title> <p>Background: The outcome and longitudinal course of inflammation and infection markers were unknown in COVID-19 patients on the ICU treated without (N) or with SARS-CoV-2 specific monoclonal antibodies (casirivimab / imdevimab, C) or antibodies against interleukin-6 (IL-6) receptors (tocilizumab, T), solely, or in combination of both (C + T). <h4>Methods:</h4> In a retrospective observat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
df7208d8-a570-5d5c-8930-2060875de491
DOI
10.21203/rs.3.rs-4090027/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational studyDOI 10.21203/rs.3.rs-4090027/v1
An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcomeSemantic proximity
A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity
Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity
Cycle threshold SARS-CoV-2 RT-PCR and bronchoalveolar cytokine concentrations redefine the COVID-19 phenotypes in critically ill patientsSemantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID SyndromeSemantic proximity
Assessment of longitudinal changes in immune responses in critically ill adults with COVID-19Semantic proximity
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort studySemantic proximity
Dynamic changes in serum IL-6, IL-8, and IL-10 are associated with the outcome of patients with severe COVID-19 in ICUSemantic proximity
Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patientsSemantic proximity
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity
Select a neighboring publication to make it the new centre.